Arman Altincatal Selected Research

peginterferon beta-1a

4/2022	Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients.
1/2022	Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
1/2022	Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
1/2021	Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate.
1/2021	COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Arman Altincatal Research Topics

Disease

6	Multiple Sclerosis 04/2022 - 01/2021
4	Infections 01/2021 - 05/2014
2	Disease Progression 01/2022 - 01/2021
1	Injection Site Reaction 01/2022
1	Relapsing-Remitting Multiple Sclerosis 01/2022
1	COVID-19 01/2021
1	Severe Acute Respiratory Syndrome 01/2021
1	Gram-Negative Bacterial Infections 01/2019
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2019
1	Neoplasms (Cancer) 01/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Intraabdominal Infections 01/2019
1	Sepsis (Septicemia) 01/2019
1	Urinary Tract Infections (Urinary Tract Infection) 01/2019
1	Fatigue 01/2018
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018
1	Dyspnea (Shortness of Breath) 01/2018
1	Opioid-Induced Constipation 01/2016
1	Constipation 01/2016
1	Chronic Hepatitis C 05/2014
1	Thrombocytopenia (Thrombopenia) 05/2014
1	Liver Diseases (Liver Disease) 05/2014
1	Hypertension (High Blood Pressure) 04/2013
1	Heart Failure 04/2013
1	Esophageal and Gastric Varices (Esophageal Varices) 02/2013
1	Hemorrhage 02/2013
1	Dementia (Dementias) 01/2012
1	Alzheimer Disease (Alzheimer's Disease) 01/2012
1	Hyperammonemia 04/2004

Drug/Important Bio-Agent (IBA)

5	peginterferon beta-1aIBA 04/2022 - 01/2021
3	Hemoglobins (Hemoglobin)IBA 05/2014 - 02/2013
2	Dimethyl FumarateIBA 01/2022 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2012
2	InterferonsIBA 01/2021 - 05/2014
2	Glatiramer Acetate (Copaxone)FDA Link 01/2021 - 01/2021
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022
1	diroximel fumarateIBA 01/2021
1	Interferon beta-1a FDA Link 01/2021
1	Natalizumab (Tysabri)FDA Link 01/2021
1	Carbapenems (Carbapenem Antibiotics)IBA 06/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	TOR Serine-Threonine KinasesIBA 01/2019
1	HematinicsIBA 01/2018
1	Lenalidomide (CC 5013)FDA Link 01/2018
1	Opioid Analgesics (Opioids)IBA 01/2016
1	naloxegolIBA 01/2016
1	Ribavirin (Virazole)FDA LinkGeneric 05/2014
1	Erythropoietin FDA Link 04/2013
1	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA 01/2012
1	Investigational DrugsIBA 04/2004
1	phenylacetic acid (phenylacetate)FDA Link 04/2004
1	Urea (Carbamide)FDA LinkGeneric 04/2004
1	Sodium Benzoate FDA Link 04/2004
1	EnzymesIBA 04/2004

Therapy/Procedure

8	Therapeutics 04/2022 - 01/2019
1	Time-to-Treatment 01/2022
1	Length of Stay 01/2019
1	Erythrocyte Transfusion 01/2018